Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesVincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: childrens oncology group study d9803
Journal of Clinical Oncology, 10/08/09
Arndtet CAS et al. – For intermediate-risk RMS, VAC/VTC does not significantly improve FFS compared with VAC.
Methods- Patients randomly assigned to 39 weeks of VAC versus VAC/VTC
- Local therapy began after week 12
- Patients with parameningeal RMS with intracranial extension (PME) treated with VAC and immediate x-ray therapy
- Primary study end point was failure-free survival (FFS)
- Designed with 80% power (5% two-sided level) to detect increase in 5-year FFS from 64% to 75% with VAC/VTC
- 617 eligible patients were entered onto the study: 264 were randomly assigned to VAC and 252 to VAC/VTC; 101 PME patients were nonrandomly treated with VAC
- Treatment strata embryonal RMS, stage 2/3, group III (33%); embryonal RMS, group IV, less than age 10 years (7%); alveolar RMS or undifferentiated sarcoma (UDS), stage 1 or group I (17%); alveolar RMS/UDS (27%); and PME (16%)
- Median follow-up of 4.3 years, 4-year FFS was 73% with VAC and 68% with VAC/VTC
- No difference in effect of VAC versus VAC/VTC across risk groups
- The frequency of second malignancies was similar between the 2 treatment groups
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue
Journal of Neuro-Oncology, 12/04/09
Current Approach to Pediatric Soft Tissue Sarcomas
The Oncologist, 12/03/09
Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia
Hematology, 12/02/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor